ArticleChemical research in toxicology2026
Mitochondrial DNA Damage Induced by Aristolochic Acid I: Recognizing the Heart as a Target Organ.
Article in Chemical research in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We revealed in this study that prolonged aristolochic acid I (AA-I) exposure leads to an increase in oxidative stress level, and decreases in mitochondrial DNA (mtDNA) copy numbers and ATP levels in the heart, kidneys, and liver of exposed mice. The most significant decreases in ATP levels were observed in the heart and kidneys, both of which are high-energy-consuming organs. Additionally, high levels of AA-DNA adducts were detected in the mtDNA isolated from the kidneys. These combined observations of AA-induced mitochondrial dysfunction in key energy-consuming organs may help explain previous observations of rapidly progressive renal failure and the later onset of milder hypertension in patients with aristolochic acid nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.